May 29 |
Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24
|
May 13 |
Artelo Biosciences GAAP EPS of -$0.78
|
May 13 |
Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
|
May 10 |
Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14th
|
Apr 23 |
Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy
|
Apr 22 |
Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time
|
Mar 25 |
Recap: Artelo Biosciences Q4 Earnings
|
Mar 25 |
Artelo Biosciences GAAP EPS of -$3.14 misses by $0.58
|
Mar 25 |
Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update
|
Mar 12 |
Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge
|